In addition to NSCLC, the amplification of EGFR expression and signaling is a common feature in a variety of human cancers including prostate, gastric, ovarian, colorectal, renal, breast, glioma and head and neck cancers [37–39]. This evidence concerns the gene EGFR and glioma.